Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) had its target price upped by investment analysts at Morgan Stanley from $130.00 to $133.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley‘s price objective suggests a potential upside of 79.88% from the stock’s previous close.
Other equities research analysts have also issued research reports about the company. Zacks Research lowered Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. Barclays reaffirmed an “overweight” rating and issued a $145.00 price target (up from $128.00) on shares of Monopar Therapeutics in a report on Friday, September 11th. BTIG Research reiterated a “buy” rating on shares of Monopar Therapeutics in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Monopar Therapeutics in a research note on Thursday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $123.12.
Get Our Latest Research Report on Monopar Therapeutics
Monopar Therapeutics Stock Performance
NASDAQ MNPR traded up $1.94 on Monday, hitting $73.94. The stock had a trading volume of 30,128 shares, compared to its average volume of 202,448. The firm has a 50-day moving average of $82.59 and a 200-day moving average of $77.41. Monopar Therapeutics has a 52-week low of $50.07 and a 52-week high of $124.82. The company has a market capitalization of $496.29 million, a price-to-earnings ratio of -30.65 and a beta of 1.62.
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.72) earnings per share for the quarter, hitting the consensus estimate of ($0.72). As a group, research analysts anticipate that Monopar Therapeutics will post -2.96 earnings per share for the current fiscal year.
Insider Transactions at Monopar Therapeutics
In other Monopar Therapeutics news, Director Christopher Starr sold 8,400 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $78.50, for a total transaction of $659,400.00. Following the sale, the director owned 5,173 shares in the company, valued at $406,080.50. This trade represents a 61.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chandler Robinson sold 29,056 shares of the firm’s stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $88.00, for a total value of $2,556,928.00. Following the sale, the chief executive officer owned 99,267 shares in the company, valued at $8,735,496. The trade was a 22.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 51,920 shares of company stock worth $4,527,913 in the last three months. Insiders own 9.70% of the company’s stock.
Hedge Funds Weigh In On Monopar Therapeutics
A number of large investors have recently modified their holdings of MNPR. Meeder Asset Management Inc. lifted its holdings in shares of Monopar Therapeutics by 18.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 1,651 shares of the company’s stock worth $132,000 after acquiring an additional 262 shares during the last quarter. Sei Investments Co. grew its holdings in shares of Monopar Therapeutics by 9.5% during the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock valued at $415,000 after purchasing an additional 656 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in Monopar Therapeutics in the 1st quarter worth $250,000. Bank of New York Mellon Corp raised its position in Monopar Therapeutics by 21.2% in the 1st quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock worth $4,307,000 after purchasing an additional 13,761 shares during the period. Finally, ADAR1 Capital Management LLC boosted its position in Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after buying an additional 30,370 shares during the period. 1.83% of the stock is owned by hedge funds and other institutional investors.
About Monopar Therapeutics
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.
Further Reading
- Five stocks we like better than Monopar Therapeutics
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
